Accessing Library
Connecting to Pep Nation Lab's research database...
Connecting to Pep Nation Lab's research database...
Select Up To Four Compounds To Review Their Evidence, Targets, And Handling Side By Side.
For Laboratory Research Only
| Attribute | ||
|---|---|---|
Research Summary | CJC-1295 with DAC is a messenger that tells your brain to release more growth hormone. The "DAC" part acts like a super-glue, making the messenger stick around in your blood for a whole week instead of disappearing quickly. | CJC-1295 (without DAC) acts like a quick tap on the shoulder to your brain, telling it to squirt out a pulse of growth hormone right now. It gets in, does its job fast, and gets out of your system. |
Studied For | GH pulsatile release researchGH-axis anti-agingGrowth hormone deficiencyExtended GH secretionAnti-aging / longevity via GH axisMuscle growth via GH axisBody composition improvementFat reduction via GHSleep quality enhancementIGF-1 elevation researchRecovery and repair via GH axisBone density via GH stimulationCollagen synthesis via GH axisMetabolic rate increaseAdult GH deficiency modelsGH secretagogue researchcontinuous GH releasemuscle growthfat lossIGF-1 elevationrecovery | Pulsatile GH simulationGH secretagogue researchSleep quality improvementStacked with ipamorelin for synergistic GH releaseAnti-aging via GH axisBody composition / lean massGH deficiency modelsFat loss via GH axisRecovery and tissue repair via GHBone density supportIGF-1 elevationCollagen synthesis promotionSkin quality researchAthletic performance researchGH pulse amplitude enhancementmuscle growthfat lossdeep sleepanti-agingvitalitycollagen productionrecovery |
Research Areas | Performance & MuscleLongevityMetabolicJoint & Bone Support | Performance & MuscleLongevityMetabolicJoint & Bone SupportSleep & Circadian |
Best Stacked With | ipamorelinghrp-6bac-water | ipamorelinghrp-6ghrp-2sermorelinbac-water |
Overview | ||
Category | Muscle Growth & Performance | Muscle Growth & Performance |
Compound Class | Long-acting synthetic GHRH analog with Drug Affinity Complex (DAC) albumin-binding moiety | Short-acting synthetic GHRH analog (Mod GRF 1-29); no albumin-binding DAC moiety |
Molecular Target | GHRH receptor (GHRHR) on pituitary somatotrophs; sustained GH and IGF-1 elevation | GHRH receptor (GHRHR) on anterior pituitary somatotrophs; augments natural pulsatile GH release |
Aliases / AKA | CJC-1295 DACCJC 1295 with DACCJC1295 DACGHRH analog with DACCJC-1295 Drug Affinity ComplexDAC-GRF | CJC-1295 no DACMod GRF 1-29Modified GRF 1-29Modified GRFModGRFCJC1295 without DAC |
Parent Compound | Growth hormone releasing factor | Growth hormone releasing factor |
Molecular Weight | 3647.1 Da | 3357.9 Da |
Amino Acid Sequence | tetrasubstituted GRF(1-29) + DAC | tetrasubstituted GRF(1-29) amide |
CAS Number | 446262-90-4 | 863288-34-0 |
Year Discovered | Not Listed | Not Listed |
Pro-Angiogenic | No | No |
GLP-1 Class | No | No |
Purity | Not Listed | Not Listed |
Identity | ||
Evidence Tier | ||
Risk Level | ||
PubMed Citations | 2 Sparse | 5 Sparse |
Clinical Trials | 11 Active | 11 Active |
Regulatory Status | Not FDA-approved; research chemical; WADA S2. | Not FDA-approved; research chemical; WADA S2. |
Evidence & Regulatory | ||
Half-Life | ~6-8 days (albumin-bound, DAC) | ~30 min (pulsatile) |
Typical Frequency | Not Listed | Not Listed |
Administration Route | Injection Only | Injection Only |
Mechanism / PK | Not Listed | Not Listed |
Reported Findings | A 2006 human Phase 1/2 study showed single doses raised growth hormone for about 6 days and IGF-1 for 9 to 11 days. Limited evidence beyond early trials. | Mechanistic plausibility rests on native GHRH physiology and on GHRH-plus-GHRP synergy. Controlled trials of this specific analog are sparse; preliminary. |
Side Effects Noted | Injection-site reactions, facial flushing, headache, water retention. Sustained non-pulsatile growth-hormone elevation raises a theoretical desensitization concern. | Injection-site reactions, flushing, headache, lightheadedness, mild water retention; short half-life limits exposure. |
Warnings | Not approved; no chronic-use safety data; general growth-hormone-axis risks apply. WADA-prohibited. Research use only. | Not approved; growth-hormone-axis risks apply. WADA-prohibited. Frequently mislabeled simply as CJC-1295 without the DAC distinction. Research use only. |
Pharmacology | ||
Form | lyophilized | lyophilized |
Diluent | bacteriostatic or sterile water | bacteriostatic or sterile water |
Storage Temp | cold, dark | cold, dark |
Light Sensitive | Yes | Yes |
Freeze / Thaw | avoid | avoid |
Handling Notes | Reactive DAC maleimide is moisture-sensitive. | Short half-life; often co-administered with a GHRP. |
Reconstituted Shelf Life | 28 Days Refrigerated | 28 Days Refrigerated |
Handling & Storage | ||
Pep Nation Lab's comparison tool puts research-grade peptides and compounds head to head - mechanism of action, molecular target, evidence tier, molecular weight, sequence, half-life, and documented research focus - so qualified researchers can evaluate the differences that matter. Every data point is drawn from a referenced monograph. For in vitro laboratory research use only.
The two most-studied research peptides for tissue repair and recovery.
Single GLP-1 versus dual GLP-1/GIP incretin agonists in metabolic research.
Dual versus triple incretin receptor agonists in weight-research models.
A GLP-1 agonist versus a triple-agonist incretin in metabolic research.
A GHRH analog versus a selective ghrelin-receptor secretagogue.
A ghrelin-receptor secretagogue versus a GHRH analog for growth-hormone research.
Two GHRH analogs studied on the growth-hormone axis.
The two first-generation growth-hormone releasing peptides.
An amylin analog versus a GLP-1 agonist in metabolic research.
A mitochondrial-derived peptide versus an HGH fragment in metabolic research.
Melanocortin versus kisspeptin pathways in reproductive research.
A telomerase-pathway peptide versus NAD+ metabolism in longevity research.
A potent versus a highly selective ghrelin-receptor secretagogue.
Two GHRH analogs with contrasting half-life profiles.
A direct IGF-1 analog versus a growth-hormone secretagogue.
The DAC versus non-DAC forms of the CJC-1295 GHRH analog.
Two Russian-developed nootropic and anxiolytic research peptides.
Two mitochondrial-targeted peptides in cellular-energy research.
Two immune-modulating research peptides with distinct mechanisms.
Two HGH-fragment analogs studied for fat-metabolism research.
Next-generation multi-receptor incretin agonists in metabolic research.
Browse the full research catalog or the A To Z index to compare any compound.
Any research-grade compound in the library can be placed side by side - up to four at a time. The tool compares mechanism of action, molecular target, evidence tier, molecular weight, amino acid sequence, reported half-life, and what each compound has been studied for, all drawn from referenced monographs.
The evidence tier reflects how extensively a compound has been studied in the referenced literature, from early preclinical signals through to compounds with human clinical data. It is a research-quality signal only, never a safety or efficacy endorsement.
Each comparison page is generated from the same referenced compound database - a genuine side-by-side of mechanism, identity, pharmacokinetics, and evidence, plus data-derived key differences. They are curated, not auto-generated thin pages.
No. Every comparison is for in vitro laboratory research use only. Nothing here is medical advice, a treatment recommendation, or dosing guidance, and no product is for human or animal consumption.
